Zomedica Corp. (NYSEAMERICAN:ZOM) VP Buys $47,998.88 in Stock

Zomedica Corp. (NYSEAMERICAN:ZOM) VP Russell Kevin Klass bought 299,993 shares of Zomedica stock in a transaction on Wednesday, June 12th. The shares were purchased at an average price of $0.16 per share, for a total transaction of $47,998.88. Following the acquisition, the vice president now directly owns 2,000,050 shares in the company, valued at approximately $320,008. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Zomedica Stock Performance

NYSEAMERICAN ZOM opened at $0.15 on Friday. Zomedica Corp. has a twelve month low of $0.12 and a twelve month high of $0.25.

Zomedica (NYSEAMERICAN:ZOM) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share (EPS) for the quarter. Zomedica had a negative net margin of 143.67% and a negative return on equity of 8.62%. The business had revenue of $6.26 million for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ZOM. Price T Rowe Associates Inc. MD lifted its stake in shares of Zomedica by 41.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 948,300 shares of the company’s stock worth $139,000 after buying an additional 276,100 shares in the last quarter. Frazier Financial Advisors LLC bought a new position in Zomedica in the 4th quarter valued at approximately $50,000. Sequoia Financial Advisors LLC purchased a new stake in Zomedica during the 4th quarter valued at $43,000. Finally, Virtu Financial LLC increased its holdings in shares of Zomedica by 1,585.0% in the 1st quarter. Virtu Financial LLC now owns 168,773 shares of the company’s stock worth $25,000 after purchasing an additional 158,757 shares in the last quarter. Hedge funds and other institutional investors own 8.95% of the company’s stock.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.